Could a diabetes drug help heart shock patients?

NCT ID NCT07450417

Ongoing Disease control Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether starting empagliflozin early in patients with cardiogenic shock (a severe heart pump failure) can reduce deaths and hospital readmissions within 3 months. Researchers compared 418 patients who received the drug plus usual care against those who got usual care alone. The goal is to see if this well-tolerated heart failure drug can improve outcomes in this critical condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: empagliflozin (SGLT2 inhibitor)
What this could lead to: If it works, this could point toward a new standard treatment for cardiogenic shock, potentially lowering death rates and hospital readmissions.
What could go wrong: This is a small, retrospective, single-center study, not a large randomized trial. Results may not apply to all patients, and the drug's safety in shock is still being explored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOGENIC SHOCK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiogenic shock heart failure Shock, Cardiogenic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOGENIC SHOCK

Contacts and locations

Show contact details

Locations

Chru Nancy

Vandœuvre-lès-Nancy, 54500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.